By Nigam Arora & Dr. Natasha Arora
Game Changer
Merck (MRK) has announced that its oral antiviral pill molnupiravir reduces the death risk from COVID by 50%. 7.3% of those who received the pill were either hospitalized or died through Day 29 compared with 14.1% of those who received the placebo. The data was so positive that the study was stopped early.
Merck plans to seek Emergency Use Authorization.
Technicals
The first resistance zone for MRK is $81.75 to $84. The second resistance zone is $86.47 to $88.41. The resistance is likely to slow the move up in a normal market. However, if the momo crowd gets hold of this stock, they can quickly move it above $100.
Fundamentals
MRK is a very large company. Although this drug will be meaningful, do not expect the stock to double or triple as small biotech stocks do on good news. The probability is very high of something similar to Pfizer – PFE has had tremendous success with a vaccine against COVID but the stock has been slow to move.
MRK has a nice dividend of 3.46%.
Zones
For those who are following the Good Way, and are super aggressive, the Buy Now rating is🔒 (To see the locked content, please take a 30 day free trial).
For those following the Best Way, the buy zone is 🔒. MRK is trading at $80.94 as of this writing in the premarket.
To learn about the Good Way and the Best Way, please study your Getting A Running Start Guide.
The mental stop zone is $68.13 – $69.43.
Long term target zone is $115 – $125.
The maximum recommended quantity is 25% of full core position size.
To take a free 30-day trial to paid services to gain access to more opportunities, please click here.
This post was just published on ZYX Buy Change Alert.
Markets can generate substantial wealth for knowledgeable investors. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 2% of the content from our paid services. …TO RECEIVE REMAINING 98% INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES,
TAKE A FREE TRIAL TO PAID SERVICES.
Please click here to take advantage of a FREE 30 day trial.
Nigam Arora
Nigam Arora is known for his accurate stock market calls. Nigam is a distinguished master of the macro. He is a popular columnist with over 100 million page views, an engineer, and nuclear physicist by background. Nigam has founded two Inc. 500 fastest growing companies and has been involved in over 50 entrepreneurial ventures. He is the developer of Theory ZYX of Successful Change Management and is the author of the book on Theory ZYX, as well as the developer of the ZYX Change Method for Investing.
Dr. Natasha Arora
Dr. Natasha Arora has significant expertise in investment analysis especially biotech, healthcare, and technology. Natasha is a graduate of Harvard Medical School followed by a postdoc at MIT. She has published several peer reviewed research papers in top science journals.
